Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.